07:29 AM EDT, 06/05/2025 (MT Newswires) -- Knight Therapeutics ( KHTRF ) said Thursday that it has sealed an agreement to commercialize three Sumitomo Pharma America medications in Canada., for an upfront cost of $25.4 million and sales milestone payments of up to $15.75 million. Knight will also pay $7 million for inventory over the next eight months.

The three medicines to be distributed in Canada are Myfembree, Orgovyx (relugolix) and vibegron.

Knight will also acquire certain mature products, which, for the year ended March 2025, generated $11.2 million in revenue.